In this review:
Final analysis of AGO DESKTOP III/ENGOTov20 trial
Secondary cytoreductive surgery in later ROC
Final OS results from SOLO2/ENGOT-ov21
Olaparib vs cediranib + olaparib with standard platinum-based chemotherapy in recurrent platinum-sensitive OC
Mirvetuximab soravtansine + bevacizumab in patients with platinum-agnostic OC
Final results from the KEYNOTE-100 trial of pembrolizumab for advanced ROC
SCS +/- carboplatin HIPEC in patients with recurrent platinum-sensitive EOC
Concordance between CA-125 and RECIST PD in patients with germline BRCA-mutated platinum-sensitive, ROC treated with maintenance PARPi
Final survival analysis of NSGO-AVANOVA2/ ENGOT-OV24 trial
Low rates of BRCA1 and BRCA2 testing for patients with OC
Please login below to download this issue (PDF)